IDEXX Laboratorie…
USUSDIDEXX Laboratories Inc (US:IDXX) — Biotechnology: In Vitro & In Vivo Diagnostic Substances. Number of exchanges where the company shares trade: 2. On this page — price and chart, dividends, top holders and share count history.
About the company
- Website
- idexx.com
- Investor relations
- idexx.com/en/about-idexx/investors/
- Sector
- Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Westbrook, United States
- Management
- Latest reports
- Employees
- 5 000
- Founded
- 1983
- IPO
- 1991-06-21
- Shares outstanding
- Free float
- 78.5 M
- Market cap
- 45.38 B USD
- Insiders
- 0.22%
- Institutions
- 96.73%
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances
- Legal form
- XTIQ
- ISIN
- US45168D1046
- LEI
- OGMTXK0LUU1HKV2P0J84
- P/EP/E (Price / Earnings) — how many years of the company's profit you pay for a share. Calculated: current price ÷ net earnings per share over the last 12 months. Lower means cheaper relative to profit. Not calculated when the company has a loss (—).
- 47.1
- EPSEPS (Earnings Per Share) — the company's net profit over the last 12 months divided by the number of its shares, in the currency of this listing. A negative value (red) means a loss. P/E is the share price divided by EPS.
- 14.84 USD
- |P/B (price to book) — share price ÷ shareholders' equity per share from the latest balance sheet. Graham — as Benjamin Graham counted it: equity without goodwill, other intangible assets and preferred stock, that is tangible book value. He considered up to 1.5 acceptable for a defensive investor (green), or a product P/E × P/B up to 22.5. With negative tangible equity, Graham's P/B is not calculated.
- 29.149.0
- Graham numberGraham number — the highest price Benjamin Graham considered reasonable for a defensive investor: √(22.5 × EPS × tangible book value per share), where 22.5 = P/E 15 × P/B 1.5. A price below it (green) passes both of his limits at once. Not calculated with a loss or negative tangible equity.
- 69.02 USD price 912% above
- ROEROE (return on equity) is net income over the last 12 months divided by average shareholders' equity over those 12 months. It shows how much profit the company earns on every 100 dollars of capital. Consistently above 15% is a sign of a strong business, but a high ROE can also come from heavy debt or small equity after buybacks. One-off gains (sale of a business, revaluation, tax benefit) are excluded; «!» explains why the value differs from the reported one or is unreliable. Companies with negative equity have no ROE.
- 72.1%
- FCFFCF (Free Cash Flow) — money left to the company after operating costs and investment in equipment; dividends are safest when paid from it. Calculated: operating cash flow − capital expenditure, over the last 12 months, in the reporting currency.
- 1.30 B USD
- DebtDebt — all loans and bonds of the company per the latest report (short- and long-term), in the reporting currency. Below — how many years the company would need to repay net debt (debt minus cash) from its free cash flow: net debt ÷ FCF. Up to 3 years — good, 3–6 — moderate, over 6 — high. «Net cash» — net debt is negative.
Debt 849 M USD Cash and equivalents 198 M USD Net debt 651 M USD FCF 1.30 B USD Net debt / FCF 0.5 y Total debt / FCF 0.7 y The years shown on the page use net debt: cash on hand can be used to repay debt at any time. - 849 M USD0.5 y of FCF
- Earnings and FCF — for the 12 months to 30.09.2026 (the company's latest report).
- Net income
- NAVNAV — net asset value by the balance sheet: the company's assets minus its liabilities, the share of the company's shareholders (without other owners' stakes in its subsidiaries). Shown per share, with P/NAV — how many times the share price exceeds NAV per share (below 1 — the share costs less than its net assets on the balance sheet). Click to see what NAV is made of and its history.
Description
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Candles
Each candle is one trading day. The thick part runs from the open price to the close price: green — the day closed higher than it opened, red — lower. The thin line runs from the lowest to the highest price of the day. Hover or tap a day to see all four prices.
P/E
The share price divided by the company earnings per share for the last 12 months (EPS). It shows how many years the company would need to earn its current profit to «pay back» the price: a lower P/E means the stock is cheaper relative to earnings. The line has its own scale on the left.
For some companies earnings come from their quarterly reports: on the day of a new report P/E jumps (a purple tick at the bottom of the chart), between reports it changes only with the price. For others P/E uses current earnings, so before the latest report it is approximate. If earnings are negative, P/E is not shown.
My position
Visible only to you and only if this stock is among your open portfolio positions (purchases in the same currency as the chart exchange). From each purchase date there is a dashed line at the purchase price, and between it and each day close price — an area: green if the position is in profit, red if at a loss. If you sold part, the remainder is shown: a sale writes off the earliest purchases first. The day tooltip shows how many shares were in the position and the gain or loss in money and %.
Top holders
| Holder | Stake | Shares | Report date |
|---|---|---|---|
| Blackrock Inc. | 10.37% | 8.17 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.54% | 5.15 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.95% | 3.9 M | 2026-06-30 |
| State Street Corporation | 4.76% | 3.75 M | 2026-06-30 |
| Invesco Ltd. | 4.58% | 3.61 M | 2026-06-30 |
| Geode Capital Management… | 3.25% | 2.56 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 2.5 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 2.04 M | 2026-06-30 |
| BAMCO Inc. | 2.51% | 1.98 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.17% | 1.71 M | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 1.7 M | 2026-08-31 |
| Morgan Stanley | 1.72% | 1.36 M | 2026-06-30 |
| Bank Of New York Mellon… | 1.51% | 1.19 M | 2026-06-30 |
| Arrowstreet Capital, Lim… | 1.35% | 1.07 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 1.05 M | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 1.02 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.23% | 966 425 | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 1.2% | 942 289 | 2026-06-30 |
| BARON SELECT FUNDS-Baron… | 1.07% | 846 300 | 2026-06-30 |
| Amcap Fund | 0.93% | 732 861 | 2026-06-30 |
| MAZELSKY JONATHAN JAY (C… | ≈0.11% | 83 803 | 2026-02-27 |
| MCKEON BRIAN P (Chief Fi… | ≈0.06% | 49 599 | 2025-02-14 |
| HUNT NIMRATA K (Officer) | ≈0.02% | 18 300 | 2026-03-03 |
| ERICKSON MICHAEL G (Offi… | ≈0.02% | 15 092 | 2026-02-19 |
| FENNELL GEORGE (Officer) | ≈0.01% | 10 433 | 2026-06-01 |
| KINGSLEY LAWRENCE D (Dir… | ≈0.01% | 9 568 | 2026-09-04 |
| VANDEBROEK SOPHIE V (Dir… | ≈0.01% | 9 078 | 2026-05-07 |
| LANE MICHAEL J (Officer) | ≈0.01% | 8 615 | 2026-02-13 |
| UNDERBERG SHARON E (Gene… | ≈0.01% | 7 137 | 2026-03-03 |
| EMERSON ANDREW (Chief Fi… | ≈0.01% | 4 421 | 2026-08-20 |
